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xABSTRACT
Steele, Hannah E. M.S., Purdue University, May 2018. Mechanotransduction of Sub-
cellular AMPK and its Role in Breast Cancer Cell Migration. Major Professor:
Sungsoo Na.
The biophysical microenvironment of the tumor site has significant impact on
breast cancer progression and metastasis. The importance of altered mechanotrans-
duction in cancerous tissue through the integrin-mediated signaling axis has been
documented, yet its role in the regulation of cellular metabolism and the potential
link between cellular energy and cell migration remain poorly understood.
In this study, we investigated the role of mechanotransduction (via Src and FAK)
in AMP-activated protein kinase (AMPK) activation in breast cancer cells in re-
sponse to interstitial fluid flow. Additionally, we explored the involvement of AMPK
in breast cancer cell migration. An in-vitro three-dimensional (3D) cell culture model
utilizing collagen-Matrigel matrices was used. Interstitial fluid flow was applied to
the 3D cell-matrix construct inside a flow chamber. The sub-cellular signaling activ-
ity of Src, FAK, and AMPK was visualized in real-time using fluorescent resonance
energy transfer (FRET). We observed that breast cancer cells (MDA-MB-231) are
more sensitive to interstitial fluid flow than normal epithelial cells (MCF-10A) in the
regulation of FAK and Src. AMPK was activated in the mitochondria of MDA-MB-
231 cells by interstitial fluid flow, but not in other subcellular domains (i.e., cytosol,
plasma membrane, and nucleus). Subcellular AMPK in MCF-10A cells did not re-
spond to interstitial fluid flow. The inhibition of FAK or Src abolished flow-induced
AMPK activation in the mitochondria of MDA-MB-231 cells. We also observed that
global AMPK activation reduced MDA-MB-231 cell migration. Interestingly, specific
xi
AMPK inhibition in the mitochondria reduced cell migration and blocked interstitial
fluid flow-induced cell migration.
Our results suggest the linkage of FAK/Src and mitochondria-specific AMPK
in mechanotransduction and the dual role of AMPK in breast cancer cell migration
depending on its subcellular activation. Therefore, subcellular AMPK activation may
play an important and distinct role in cancer invasion and progression.
11. INTRODUCTION
More than 80% of cancers in human adults are carcinomas cancers arising from
the malignant transformation or mutation of epithelial cells [1], malignant cells form
primary tumors that damage surrounding tissue and alter the biochemical and me-
chanical properties of the extracellular matrix (ECM). Changes in the mechanics of
cancerous breast tissue include increased stiffness, interstitial fluid flow, and intersti-
tial fluid pressure [2–9]. These physical changes increase the stresses experienced by
breast cancer cells, encouraging a metastatic phenotype and migration away from the
primary tumor site [3–5, 7–10]. Both cell sensing and migration responses are me-
diated by focal adhesions that connect the intracellular cytoskeletal network to the
ECM. Focal adhesions transduce mechanical stimuli to cells via integrin-mediated sig-
naling, which includes integrin-associated protein kinases Src and FAK. Both Src and
FAK are up-regulated in cancer cells, enabling increased cell motility. One possible
downstream target of Src and FAK is the master metabolic regulator AMPK. Global,
cellular AMPK is down-regulated in cancer cells, but its paradoxical effects in tumor
growth, proliferation, and migration suggest that AMPK may play antagonistic roles
in various subcellular domains.
1.1 Epithelial breast tissue
1.1.1 Tissue and cell types
Breast tissue can be broken down into two major parts the mammary glands (and
their connected ducts) and the supporting stroma. Mammary glands and ducts are
composed of epithelial cells and make up 20% of total breast tissue [11]. Fig. 1.1 below
shows the cross-sectional structure of a mammary duct. The duct is lined by three
2types of epithelial cells luminal cells, myoepithelial cells, and epithelial progenitors [1].
It is from these ductal cells that most all breast cancers arise [1, 11,12], and invasive
luminal carcinoma is the most common type of breast cancer [13].
Fig. 1.1.: Diagram showing the luminal structure of a mammary duct [1].
The basement membrane around mammary ducts is composed of collagen IV,
laminin, entactin, and proteoglycans [12, 13]. Surrounding the basement membrane
of mammary ducts is the supporting stroma, which makes up 80% of breast tissue [11],
interstitial dense connective tissue, loose connective tissue, and blood vessels. Major
stromal cells include adipocytes, which remain in fat tissue, and fibroblasts that
maintain and secrete/replace the ECM of connective tissue [3, 11].
1.1.2 Extracellular matrix
The extracellular matrix (ECM) is a dynamic amalgamation of water, proteins,
and polysaccharides that surrounds and supports the cells within tissues [12]. The
solid phase of ECM consists of collagen I, laminin, elastin, fibronectin, glycoproteins,
and proteoglycans [11–13]. Glycoproteins are (glycosylated) proteins with saccha-
ride/carbohydrate chains attached to their amino side-chains. Proteoglycans are
heavily glycosylated proteins composed of a core protein with many glycosamino-
glycan (GAG) side chains. Proteoglycans (i.e. heparin sulfate) form large complexes
3with collagen fibers and act to stabilize and fill the ECM [12]. Collagen, elastin, and
fibronectin form a fibrous mesh that fills and structuralizes the ECM of connective
tissue. Type I collagen is the predominant fiber in ECM, and is therefore the primary
regulator of tensile properties within the tissue [13]. Fibers support cells by providing
adhesion sites for them to attach (focal adhesions). These cell-matrix adhesions en-
able intracellular tension homeostasis, migration, and mechanotransduction through
the tissue [12]. Additionally, the liquid phase of ECM exerts fluid shear stress to
embedded cells via interstitial fluid flow [7].
1.1.3 Interstitial fluid flow
Interstitial fluid, sometimes called tissue fluid, is the medium found within the
ECM [7]. With every heartbeat, nutrient- and oxygen-rich plasma leaks from capil-
laries into the stromal space to nourish cells there. Most interstitial fluid returns to the
cardiovascular system via post-capillary venules, and some filters through the inter-
stitium toward the lymphatic vessels, creating regular interstitial fluid flow (IFF) [7].
The physiological IFF rate is estimated to range from 6-60 µm/s, creating a pulsatile
shear stress of about 1 dyne/cm2 (or 0.1 Pa) within the ECM [4]. The shear stress ex-
perienced by cells embedded in a porous ECM is likely higher around the cell surface,
generating a shear stress of several Pascal on cells [6]. In healthy tissue, this shear
stress is sensed and regulated by fibroblasts inside the ECM. Stromal fibroblasts exert
tension on collagen fibers of the ECM via focal adhesions, contracting or relaxing to
regulate fluid flow [2]. In cancerous tissue, however, IFF is highly irregular.
1.2 Epithelial breast cancer tissue
1.2.1 Tumor site ECM and IFF
Malignant, epithelial mammary cells form primary tumors out of mammary ducts
and into the surrounding ECM. Tumor growth places unwanted pressure on its con-
4fined ECM, increasing IFF [2,7]. Additionally, the internal tumor pressure (ITP) can
be 100 times greater than surrounding healthy tissue, creating a pressure gradient
outward from the tumor site [4,7]. This pressure gradient interrupts normal intersti-
tial fluid flow patterns, which can no longer drain correctly, further increasing the rate
of IFF and causing fluid build-up [7]. Rapidly proliferating tumor cells begin stimu-
lating matrix metalloproteinases (MMPs) to break down collagen around the tumor.
Cancer cells also secrete high levels of inflammatory cytokines that recruit immune
cells to the site [12]. Additionally, increased IFF and tumor secretions prompt stromal
fibroblasts to become cancer-associated fibroblasts (CAFs) [3]. CAFs begin deposit-
ing collagen I and III, laminin, elastin, and fibronectin at an unusual rate, increasing
the fibrous density of the ECM even further [3,12]. In addition to fibrotic matrix de-
position, CAFs secrete high levels of TGF- and VEGF, which enhance tumor growth
and angiogenesis [3, 4]. New (and irregular) blood vessels grow into the tumor to
keep up with its metabolic expenditure [2, 7]. Figure 1.2 (below) shows increased
matrix deposition, immune cell response, and irregular blood vessel formation in tu-
morigenic tissue. The vicious cycle continues as increased ECM fibers, vessel density,
and inflammatory cell recruitment contribute to increased interstitial fluid flow [2].
Abnormally high IFF in cancerous tissue and its consequences on the biophysical
environment are known to promote cancer cell metastasis and invasion [3–5,7, 9].
5Fig. 1.2.: Illustration showing (a) normal connective tissue versus (b) cancerous
tissue [2].
1.2.2 IFF in breast cancer migration
The tumor microenvironment is damaging to healthy mammary tissue, and may
cause pain or discomfort to the patient. The real danger, however, is metastasis of
breast cancer cells from the primary tumor site to distal parts of the body. The
general steps of breast cancer metastasis are shown below in Figure 1.3. Once a
primary tumor has been formed and vascularized, cells detach from the tumor site
and migrate toward blood vessels [4,10]. Individual cancer cells then squeeze through
the endothelial lining of vessels and circulate through the blood stream to distal parts
of the body. Finally, cells adhere to and exit the blood vessel, forming a secondary
tumor site in adjacent tissue [10]. Breast cancer cells migrate preferentially to bone,
where they degrade bone tissue and inhibit red and white blood cell production [14].
Ultimately, it is cancer cell metastasis, rather than primary tumor formation, that
proves fatal. Since most patients are diagnosed after primary tumor formation and
vascularization, the obvious target for cancer therapy is the prevention of metastasis.
The interaction of both mechanical and biochemical stimuli and the complexity of
intracellular signaling make the targets of initial metastasis difficult to identify.
6Fig. 1.3.: A schematic showing the metastatic cascade. Cancerous cells from the
primary tumor are prompted to invade the ECM and migrate toward blood vessels.
Cancer cells enter the bloodstream (intravasation), circulate to distal parts of the
body, and exit the circulatory system (extravasation) to form a secondary tumor
site [10].
As mentioned previously, increased IFF at the tumor site promotes cancer cell
invasion. High IFF stimulates CAFs to deposit high volumes of ECM, namely colla-
gen [3,12]. An ECM high in fibrous content increases breast cancer cell migration for
two reasons. First, fibrotic deposition increases ECM stiffness, which is known to stim-
ulate breast cancer cell migration in multiple cell lines, including highly metastatic
MDA-MB-231 cells [4,7,8,10,12]. The stiffness of healthy mammary tissue has been
estimated to be 200 Pa, while the stiffness of a breast cancer tumor can be as high
as 4000 Pa [3]. The stiffness of the ECM around the tumor can be 100 times that of
healthy tissue [7]. Second, a dense collagen matrix provides cancer cells with more
adhesive surfaces to attach via integrin-mediated focal adhesions, which are neces-
sary and active in migration [3, 7, 8, 15]. High IFF can also stimulate focal adhesions
directly via fluid shear stress. This integrin-mediated mechanotransduction has been
repeatedly observed in vitro, where application of fluid shear stress promotes can-
7cer cell migration [3–5, 7–9]. Finally, IFF induces cancer cell migration indirectly by
prompting the secretion of cytokines and growth factors. In response to fluid flow,
CAFs secrete high levels of TGF-β that encourage tumor growth, cancer cell survival,
and a migratory phenotype [3, 16]. Irregular flow also stimulates the overproduction
of growth factors such as FGF, EGF, or PDGF, all of which are known to stimulate
cancer cell migration [3, 16,17].
1.2.3 Epithelial-to-mesenchymal transition
The ability of cancer cells to migrate is largely determined by their phenotype.
Regardless of whether invasion is stimulated by growth factors, cytokines, ECM stiff-
ness, interstitial fluid flow, or a combination of these, a metastatic phenotype must
be achieved. Individual cancer cell migration is initiated through a process called
epithelial-to-mesenchymal transition (EMT) [Fig 1.4]. In this process, breast can-
cer cells lose their epithelial phenotype and transition to a mesenchymal/migratory
phenotype [10,16–18].
Fig. 1.4.: Schematic showing morphological shift of EMT [19].
Epithelial breast cells have distinct morphology tightly packed with strong ad-
herens junctions between them [Fig. 1.5]. Adherens junctions are composed of trans-
membrane proteins called cadherins. E-cadherin (epithelial cadherin) is the primary
cadherin in epithelial cell-cell binding.
8Fig. 1.5.: Diagram showing adherens junction between epithelial cells [18].
The extracellular domain of E-cadherin binds in a zipper fashion to the cadherins
of adjacent cells. The cytoplasmic cadherin-catenin complex binds to the actin cy-
toskeleton within cells [18]. When a breast cancer cell undergoes EMT and becomes
metastatic, there is a marked loss of E-cadherin expression [16–18, 20]. Loss of E-
cadherin is followed by nuclear localization of β-catenin and subsequent up-regulation
of EMT transcription factors like Snail and Twist [17]. EMT can be induced by
TGF-β and various growth factors including EGF, PDGF, FGF, and VEGF [16,17].
TGF-β activates the Smad pathway within epithelial cells, which ultimately act to
up-regulate E-cadherin suppressors [16]. Once EMT is complete, cancer cells express
high levels of vimentin [17] and focal adhesion kinase (FAK) [16], enabling cells to
migrate individually. Cells with a mesenchymal phenotype are better able to resist
apoptosis, adverse immune response, and chemotherapy [16]. Not all cancer cells mi-
grate individually some carcinomas invade the surrounding tissue collectively [16]. In
collective migration, one highly metastatic leader cell guides a linear array of cancer-
ous followers while adherens junctions are maintained [16]. Some highly metastatic
9breast cancer cell lines (such as MDA-MB-231 used in this study), however, only
migrate individually and with a mesenchymal phenotype [21].
1.3 Cell signaling and mechanotransduction
Mechanical loading plays an important role in breast cancer metastasis. Changes
in the mechanical properties of the ECM occur over weeks or months. Interstitial
fluid flow, however, can induce cellular responses within seconds/minutes. Knowledge
of upstream, integrin-mediated signaling is robust, and mechanical stimulation (via
fluid flow) of integrins at focal adhesions initiates many signaling cascades. Namely,
fluid flow-induced integrin activation plays a part in cancer cell migration. Here
we discuss AMP-activated kinase (AMPK) as one potential downstream target of
integrin-mediated mechanotransduction. Additionally, the role of subcellular AMPK
in fluid flow-induced migration of breast cancer cells is considered.
1.3.1 Integrins, Src, and FAK
Integrins are transmembrane proteins consisting of heterodimeric and subunits.
There are 16 types of α subunits and 8 β subunits which can form over 20 combi-
nations, each corresponding to a different integrin. Integrins function as receptors
for proteins of the ECM and connect them to the intracellular actin cytoskeleton. In
both normal and cancerous epithelial breast cells, β1-integrins are most commonly
expressed [22, 23]. β1-integrins bind to type I and type IV collagen, fibronectin,
vitronectin, or laminin, depending on their α subunit. The extracellular domain
of β1-integrins acts as the receptor and binding site for components of the ECM.
Integrin-matrix binding induces integrin clustering at the plasma membrane and the
formation of actin stress fibers within cells [22,24]. The cellular tension within actin
filaments is regulated by Rho GTPases (RhoA, Rac1, and Cdc42) to maintain struc-
tural homeostasis within the ECM and to mediate contractile forces in cell migra-
tion [24]. Contacts between integrin clusters and the ECM are termed focal adhesions
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and are sites of mechanical force transmission/signaling. In this way, integrins act as
the major mechanosensors for cells. The cytoplasmic domain of β1-integrin interacts
with intracellular signaling molecules or adaptor proteins that connect it to the actin
cytoskeleton [8, 22, 24]. These proteins include talin, paxillin, tensin, vinculin, FAK
and Src [8, 9, 12,24].
Fluid flow-induced shear stress exerted on metastatic breast cancer cells results in
β1-integrin activation [5, 7–9, 12]. Signals initiated at these focal adhesions are then
transduced into cells via activation of integrin-associated tyrosine kinases namely, Src
and FAK [8, 9, 12, 22, 24]. During the formation of focal adhesions, FAK is recruited
to sites of integrin clustering. It is unclear whether FAK associates directly with
the β1 subunit of integrin or depends on the co-localization of adaptor proteins talin
and paxillin [22]. Nonetheless, FAK is the first tyrosine kinase associated with the
cytoplasmic tail of integrin. Upon integrin activation, FAK auto-phosphorylates at
its Tyr-397 residue which creates a high-affinity Src binding domain (SH2) [22]. Src
then binds to FAK, altering its regulatory tyrosine residue and creating a Src-FAK
complex that can phosphorylate other molecules near the focal adhesion [22]. One
known downstream target of Src and FAK is the family of Rho GTPases, which is
activated by Src/FAK to increase cell motility [24].
FAK and Src are both highly expressed in metastatic breast cancer cells [24–
26]. FAK is necessary for cell adhesion and migration; therefore, inhibition of FAK
disassembles focal adhesions, stunts tumor growth/progression, and blocks cancer cell
migration [8,24,25]. Similarly, selective inhibition of Src hinders cancer cell migration
and ECM attachment [26]. It makes sense that inhibition of focal adhesion proteins
would discourage cell migration, since the motility of cells depends on their ability to
pull on the ECM. Just as β1-integrin activation can be initiated by flow-induced shear
stress, Src and FAK can also be activated by IFF. Additionally, integrin-Src-FAK
signaling due to interstitial fluid flow is connected to increased migration of breast
cancer cells [5, 7–9, 12]. MDA-MB-231 cells embedded in 3D collagen gel showed
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augmented migration in response to applied fluid flow, but inhibition of Src or FAK
decreased their migratory response [5].
1.3.2 AMPK
Another potential downstream target of Src/FAK is the metabolic regulator AMPK.
AMP-activated kinase (or AMPK) is a heterotrimeric kinase that senses and regu-
lates cellular energy [27–30]. AMPK is composed of three subunits one catalytic α
subunit and two regulatory subunits (β and γ). The γ subunit has four sequence
repeats that function as four adenine nucleotide-binding domains. One domain is
always bound to AMP, one is always free, and two are competitively bound by AMP,
ADP, or ATP [29]. In this way, AMPK is able to sense the ratio of AMP and ADP
to ATP, which is the usable form of energy in the cell. As the ratio of AMP:ATP
increases, the amount of viable energy inside the cell drops, and AMPK is activated.
On a molecular level, AMPK is activated when AMP binds to one of the competitive
binding domains of the γ subunit [29]. AMPK can also be activated via phosphoryla-
tion of its α subunit by the well-known tumor suppressor LKB1 [29, 30]. The effects
of AMPK activation include decreased cell growth and differentiation, increased ATP
conservation/production, and inhibited anabolic processes [30]. In a broad sense,
AMPK is activated as a result of metabolic stress, which is often a product of me-
chanical stress on the cell. Since mechanical stress is often transmitted through the
cell via integrin-mediated signaling, AMPK may be a downstream target of Src/FAK
activation.
1.3.3 Role of AMPK in cancer
As mentioned previously, AMPK is a direct substrate of tumor suppressor LKB1;
however, in cancerous cells, LKB1 is mutated while AMPK is not [30]. Regard-
less, AMPK has also been considered a metabolic tumor suppressor since it regulates
the growth and proliferation of cells. AMPK activity is always diminished in breast
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cancer, and activating AMPK in metastatic cancer cells inhibits growth [27,28,30,31].
Augmented AMPK activity is known to attenuate cancer cell migration [27, 28, 31],
and AMPK is believed to help regulate cell motility by controlling microtubule dy-
namics [31]. The efficacy of clinical AMPK activators in preventing tumor progression
and metastasis is attributed in part to the inhibition of cell migration [31]. In spite of
AMPK down-regulation in tumor cells, AMPK has garnered much attention for hav-
ing dual functions in cancer. For example, when AMPK is on it stimulates mitophagy
and enhances the metabolic flexibility/survival of cancer cells; however, AMPK ac-
tivation also stunts tumor growth and proliferation [29, 30]. When AMPK is off it
enables unchecked cancer growth and proliferation, but the metabolic plasticity of
cells is diminished [29,30]. The paradoxical nature of AMPK in cancer has led many
to believe that the role of AMPK may vary based on its subcellular location [30,32].
For example, ovarian cancer cells in 3D collagen gel display co-localization of AMPK
activation with mitochondria at the leading edge of cells during migration [33]. If
global AMPK activation reduces cancer cell migration [27, 31], but organelle-specific
AMPK activity increases during migration, how might subcellular AMPK activation
in cancer cells vary under mechanical stress?
1.4 FRET-based biosensors
FRET (fluorescent resonance energy transfer) microscopy was used to monitor ki-
nase activity in various subcellular domains during interstitial fluid flow experiments.
FRET-based biosensors are accurate tools for visualizing molecular activity inside liv-
ing cells with high spatiotemporal resolution [34,35]. FRET-based biosensors can be
manufactured by fusing donor and acceptor fluorescent proteins to additional binding
domains capable of conformational change [34,35]. For example, consider the protein
kinase FAK. A FRET-based biosensor for cytosolic-FAK contains a cyan fluorescent
protein (CFP) donor, an SH2 binding domain, a FAK substrate peptide, and a yellow
fluorescent protein (YFP) acceptor [Fig. 1.6]. In an inactive state, the fluorescent
13
proteins are in close proximity, which allows FRET from the CFP to the YFP. Cyan
excitation (433 nm) of the biosensor gives yellow emission (527 nm) [36]. When
cytosolic-FAK is activated, it will phosphorylate the FAK substrate of the biosensor.
Upon phosphorylation of the substrate, it will bind to the SH2 domain. This causes
a conformational change, separating the fluorescent proteins. Separation eliminates
the FRET from CFP to YFP. In an active conformation, the biosensor will emit
high CFP and low YFP signals. Therefore, the activation of FAK can be monitored
over time using the ratio CFP/YFP [36]. The same is true for visualizing Src kinase
activity [37,38].
Fig. 1.6.: Structure and function of a FRET-based FAK biosensor [36].
FRET biosensors can also be specified to target subcellular domains. For example,
Lyn-Src and Lyn-FAK biosensors were designed to observe Src and FAK activity at
lipid raft regions of the plasma membrane. These membrane-specific biosensors were
constructed by attaching palmitoylation sites at the N-termini of the biosensors, which
ensure the biosensors are membrane-bound [38].
FRET biosensors for AMPK operate on the same general mechanism [Fig 1.7a].
AMPK biosensors contain a CFP, an FHA1 binding domain, an AMPK substrate
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peptide, and a YFP variant (cpVE172) [32]. The difference is that an inactive confor-
mation is characterized by separated fluorescent proteins, rather than proximal ones.
Once AMPK phosphorylates the AMPK substrate peptide, it binds to the FHA1
domain. This brings the fluorescent proteins together, enabling FRET from CFP
to YFP. Thus, AMPK activation can be observed via changes in the emission ratio
YFP/CFP [32]. AMPK biosensors can also be designed to target specific subcellular
locations [Fig.1.7b]. Different fusion sequences enable attachment to the following or-
ganelles: nucleus (Nuc-AMPK), plasma membrane (PM-AMPK), and mitochondria
(Mito-AMPK) [32]. The ability to observe protein activation on a subcellular level
makes FRET biosensors valuable tools for live cell imaging.
Fig. 1.7.: Schematics showing (A) the simplified structure of a membrane-bound
AMPK FRET biosensor and (B) the locations of subcellular AMPK biosensors [32].
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2. METHODS
2.1 Biosensors and plasmids
FRET biosensors were used to observe subcellular activities of Src, FAK, and
AMPK in real time. The development and specificity of these biosensors were pre-
viously described [32, 36, 37]. The Src biosensor contains a cyan fluorescent protein
(CFP) and the SH2 domain from c-Src, connected by a flexible linker to a yellow flu-
orescent protein (YFP) and Src substrate peptide [37]. Similarly, the FAK biosensor
is comprised of a CFP, SH2 domain, YFP, and FAK substrate peptide [36]. Both Src
and FAK biosensors (Lyn-Src and Lyn-FAK, respectively) were designed to target the
lipid raft of the plasma membrane. Lipid raft-targeting biosensors were used for these
tyrosine kinases because that is where mechanosensitive integrins reside. The AMPK
biosensors consist of a CFP, an FHA1 binding domain, an AMPK substrate peptide,
and a YFP variant (cpVE172). Subcellular AMPK FRET plasmids included Cyto-
AMPK, PM-AMPK, Nuc-AMPK, and Mito-AMPK. An AMPK inhibitor peptide
(Tom20-mChF-AIP) was used to specifically inhibit Mito-AMPK. The development
and accuracy of Tom20-mChF-AIP was previously described [32]. Tom20-mChF -AIP
acted as a preferential substrate to be phosphorylated by Mito-AMPK.
2.2 Chemical reagents
PP2 (Sigma, 10 µM) was used to inhibit Src activity, and PF573228 (Sigma, 1
µM) was used to inhibit FAK. Compound C (Millipore Sigma, 5 µM) was used as a
global AMPK inhibitor. Previous studies also used a working concentration of 5 µM
for the MDA-MB-231 breast cancer cell line [39, 40]. A769662 (Tocris, 25 µM) was
used as a global AMPK activator.
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2.3 Cell culture and transfection
The human breast cancer cell line MDA-MB-231 was used. MDA-MB-231 cells
are triple negative, meaning they do not express estrogen or progesterone receptors
and do not have amplified HER-2/neu. MDA-MB-231 cells were cultured in Dulbec-
cos modified Eagles medium (DMEM, Lonza) supplemented with 10% FBS (Gibco)
and 1% penicillin/streptomycin (Lonza). The MCF10A human mammary epithe-
lial cell line was also used to represent normal non-tumor breast cells. MCF10A
cells were cultured in DMEM/F12 (Gibco) supplemented with 10% FBS (Gibco), 1%
penicillin/streptomycin (Lonza), 200 ng/mL human recombinant EGF, 50 µg/mL
hydrocortisone, and 20 µg/mL insulin (Sigma). All cells were maintained at 37 ◦C
and 5% CO2 in a humidified incubator. Lipofectamine LTX (Invitrogen) was used to
transfect biosensors/plasmids into both cell types. During transfection, cells were in-
cubated in OPTI-MEM (Gibco) serum-free, antibiotic-free media for at least 4 hours.
Low serum (1% FBS), antibiotic-free DMEM (Lonza) was then added, and cells were
incubated overnight. Cells were transfected 20-28 hours before imaging experiments.
Prior to experimentation, transfected cells were transferred to type I collagen-coated
glass-bottom dishes or µ-slide cell culture chambers (Ibidi) and incubated for at least
2 hours.
2.4 Collagen-Matrigel preparation
For 3D experiments, cells were seeded in type I collagen-Matrigel. As mentioned
previously, the ECM of mammary tumors is primarily composed of type I collagen
with small amounts of type IV collagen and laminin from the basal lamina of mam-
mary ducts [12,13]. For this reason, a small amount of basal-lamina derived Matrigel
was added to type I collagen for 3D culture. Collagen gel was prepared by adding 1
part chilled, antibiotic-free DMEM (10X) to 8 parts PureCol type I collagen solution
(Advanced BioMatrix, 3 mg/mL). Next, 1 part Matrigel (Corning, 9.8 mg/mL) was
added to the DMEM/collagen solution. The final concentration of type I collagen was
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2.4 mg/mL. The pH of the mixture was adjusted to 7.4 using sterile NaOH or HCl.
The complete collagen-Matrigel solution was warmed to room temperature, and cells
were suspended in the mixture at a density of 1x106 cells/mL. For 3D experiments
that did not require fluid flow, 100 µL of the solution (containing cells) was pipetted
into a glass-bottom dish. For 3D interstitial fluid flow experiments, 100 µL of the
mixture was injected into a 0.6 µ-slide cell culture chamber (Ibidi). Cell-gel samples
were incubated for 2 hours at 37 ◦C and 5% CO2 to form gel. Once gelation was com-
plete, low-serum (1% FBS), antibiotic-free DMEM was added to each dish/chamber,
and the samples were incubated for at least 1 hour before imaging.
2.5 Shear stress application
Fluid-flow induced shear stress was applied to both 2D and 3D cell samples grown
in µ-slide cell culture chambers (Ibidi). For 2D samples, unidirectional flow was
applied using a peristaltic pump (Cole-Parmer). The shear stress applied in 2D,
which was 10 dyne/cm2, was regulated by controlling the flow rate of the pump. The
necessary flow rate was calculated using the following equation [41]:
τ = 136.1 η φ
In this equation, τ represents shear stress, η is viscosity of the flow media (DMEM,
0.0072 dyne s/cm2), and φ is the volumetric flow rate. To achieve a shear stress of
10 dyne/cm2 in the flow chamber, a flow rate of 10.6 mL/min was employed. Before
each experiment, the 2D flow chamber and sterile connective tubing was filled with
phenol red-free DMEM (HyClone) supplemented with 1% FBS and maintained at 37
◦C [Fig. 2.1a].
For 3D collagen gel samples, unidirectional, pulsatile (0.2 Hz) flow was applied
using a syringe pump (Harvard Apparatus, PHD ULTRA). Three different flow rates
(2, 5, 10 µL/min) were used to generate a range of shear stresses on the suspended
cells. The flow chamber was connected to the syringe pump via sterile tubing filled
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with FluoroBrite DMEM (Gibco) with 1% FBS. A 13mm filter was placed at the
outlet of the flow chamber [Fig. 2.1b].
Fig. 2.1.: Diagrams showing the experimental setup for (a) 2D and (b) 3D flow
chambers.
2.6 Collagen-Matrigel characterization and compaction
The interstitial flow speed through the collagen gel was calculated by measuring
the intensity of fluorescent molecules moving through the porous cell-gel construct
over time. First, fluorescent images were taken of collagen gel inside the flow chamber
(before the addition of fluorescent probes), providing a reference for background in-
tensity. Next, Alexa Fluor 594-conjugated bovine serum albumin (BSA-594, Thermo
Fisher, 50 µg/ml) was added to the FluoroBrite DMEM (Gibco) that perfused the
flow chamber. Using the syringe pump, the fluorescent media was pushed through the
gel construct at known volumetric flow rates (2, 5, 10 µL/min) [Fig 2.2a]. Fluorescent
images were obtained every minute for 10 minutes to track the perfusion of BSA-594
through the collagen gel. After each experiment, maximum intensity images were
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captured from regions completely saturated by BSA-594. Interstitial flow speed was
calculated from the following equation [42]:
v =
L(I2 − I1)
(Imax − Ib)(t2 − t1)
L represents the length of the image (gel region being measured), and I2 and I1
are the fluorescent intensity values taken at time t2 and t1, respectively. Imax is the
maximum fluorescent intensity, and Ib is the minimum/background intensity. The
interstitial flow speed for each volumetric flow rate is shown below in Fig. 2.2b.
This range of interstitial flow speed yields a corresponding range of fluid shear
stress exerted on cells embedded in our collagen-Matrigel. Due to the small cross-
sectional area of the flow chambers and the porous nature of the gel, values for fluid
shear stress are difficult to calculate. Any approximation of shear stress would be
prone to error; however, we did estimate the permeability of our gel. Methods to
determine the Darcy permeability (k) of type I collagen gel (2.5 mg/mL), containing
cells at a density of 1*106 cells/mL, have been characterized previously [43]. The
Darcy permeability in Wang and Tarbells study was found to be 9*10−9 cm2. Our gel,
however, consisted of not only type I collagen (2.4 mg/mL), but also a small amount
of Matrigel (Corning, 0.98 mg/mL). The primary components of Matrigel, which
make up 98% of the mixture, are fibrous laminin and type IV collagen [44]. These
added components should increase the density of the fibrous mesh within collagen
gel, therefore decreasing Darcy permeability. This means the upper limit of Darcy
permeability for our gel is close to 9*10−9 cm2. On the other side of the spectrum, a
polymerized gel formed from Matrigel alone (12 mg/mL) yields a Darcy permeability
around 2.44*1010 cm2 [45]. This value represents the lower limit of permeability
for our collagen gel since the total concentration of fibrous molecules (collagen and
laminin) in our gel is 3.4 mg/mL, nearly one quarter the concentration of Matrigel
alone. Therefore, the Darcy permeability of our collagen-Matrigel lies in the range of
2.44*1010 to 9*10−9 cm2.
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Fig. 2.2.: (A) Fluorescent intensity of BSA-594 before (0 min) and after 10 minutes
of constant volumetric flow through collagen-Matrigel in a flow chamber. Scale bar,
10 µm. (B) Flow velocity (µm/min) of media through a collagen-Matrigel construct
under various volumetric flow rates (µL/min), n=4. (C) Percent gel volume
compared to control (100%) showing the compaction of collagen-Matrigel scaffolds
under various volumetric flow rates, n=4. (D) DIC images showing negligible
compaction of gel construct after 1 minute of fluid flow (10 µL/min).
The collagen gel (2.4 mg/mL) used was quite soft (with a stiffness on the order of
102 Pa), and a volumetric flow rate of 20 µL/min often ripped or pulled the collagen
construct from the wall of the flow chamber. For this reason, compaction experiments
were performed to ensure that interstitial fluid flow was not compressing suspended
cells under 2, 5, or 10 µL/min volumetric flow rates. DIC images were captured
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every 10 seconds for 1 minute to monitor initial deformation under unidirectional
flow. Volumetric change of the cell-gel construct was calculated by measuring the
movement of the gel edge in the direction of flow. Compaction experiments were
repeated four times for each flow rate. Results showed virtually no compaction of the
collagen gel under interstitial fluid flow [Fig. 2.2c].
2.7 Random migration assay
A random migration study was conducted to investigate the role of AMPK in
cancer cell migration. All migration experiments were completed in 2D inside µ-slide
flow chambers coated with type I collagen (PureCol, 100 µg/mL). MDA-MB-231 cells
were first incubated for 30 minutes with CellTracker Green CMFDA fluorescent dye
(Thermo Fisher, 20 µM). For migration under flow, cells were then seeded at low
(10-20%) confluency on µ-slide flow chambers and incubated for 2 hours, giving them
just enough time to attach. Flow chambers were then subjected to 2D fluid flow
(10 dyne/cm2) for 8 hours. For migration assays without flow, fluorescent cancer
cells were seeded at low confluency inside flow chambers and incubated for 1.5 hours.
After healthy cell attachment, floating cells were removed by replacing the media,
and some samples were treated with Compound C (5 µM) or A769662 (25 µM). The
treated cells were then incubated another 30 minutes before imaging. Antibiotic-
free, phenol red-free DMEM (1% FBS) was used for all migration experiments. Flow
chambers were kept at 37 ◦C and 5% CO2 inside a humidified incubation chamber
(Ibidi) during the migration assay. Fluorescent (GFP) and DIC images were captured
every 5 minutes for 8 hours. Imaging regions were selected to include multiple isolated
cells, away from the chamber walls and free to migrate randomly [46].
2.8 Microscopy and image analysis
All images were captured using a Nikon Ti-E inverted microscope equipped with
an EMCCD camera (Photometrics, Evolve 512) and Perfect Focus System (Nikon).
22
FRET images were acquired using CFP 438 excitation, CFP 483 emission, and YFP
542 emission wavelength (nm) filters. Green fluorescent images were captured using
a GFP 522.5 emission wavelength (nm) filter. To reduce photo-bleaching, a neutral
density (ND) 32 filter was used to control the HG lamp (Nikon). For 3D interstitial
fluid flow experiments, FRET and DIC images were taken every 2 minutes for 1
hour using a 40x objective. FRET ratio images for Src, FAK, and AMPK biosensors
were created using NIS-Elements software (Nikon) and ImageJ. Representative Src
and FAK cell images were generated as the emission ratio of CFP/YFP. In contrast,
AMPK cell images were generated as the FRET emission ratio of YFP/CFP. For
migration experiments, time-lapse images (DIC and GFP) were taken every 5 minutes
for 8 hours using a 15x objective. Cell tracking was conducted using the ImageJ
plugin TrackMate (Fiji) [47]. Cells used for tracking were chosen based on several
parameters. Free/isolated cells that stayed within the image frame, did not divide,
and did not die during the 8 hours were selected. Average distance traveled and
average migration speed was calculated in Excel (Microsoft).
2.9 Statistical analysis
All statistical data are shown as the mean ± standard error of the mean (SEM).
Statistical significance between multiple groups was determined using one-way analy-
sis of variance (ANOVA) with Dunnetts post hoc test. Statistical significance between
two groups was assessed using Students t-test. All statistical analysis was completed
using Prism 5 software (GraphPad). A p-value less than 0.05 was considered statis-
tically significant (*).
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3. RESULTS
3.1 Interstitial fluid flow regulates Lyn-Src and Lyn-FAK in a flow magnitude-
dependent manner
Fluid flow-induced shear stress initiates signals at focal adhesions that are trans-
duced into cells by tyrosine kinases Src and FAK [5,7–9,12,22,24]. We investigated the
shear mechanosensitivity of membrane-bound Src and FAK in both metastatic breast
cancer (MDA-MB-231) and non-tumor epithelial breast (MCF-10A) cells grown in
3D culture. Cells were transfected with either Lyn-Src or Lyn-FAK and suspended
in 3D collagen-Matrigel. Cell-gel mixtures were injected into separate flow chambers,
and mechanical load was applied via interstitial fluid flow. Cells were subjected to
no flow for 6 minutes, and then to 2, 5, or 10 µL/min fluid flow rates for 1 hour
[Fig. 3.1.]. Lyn-Src and Lyn-FAK activity was measured by observing changes in
CFP/YFP emission ratios. Application of 10 µL/min fluid flow induced activation of
Lyn-FAK in cancer cells (49.9% increase at 60 min) but not in normal cells. Applica-
tion of lower flow rates (2 or 5 µL/min) did not alter Lyn-FAK activity in either cell
type. Lyn-Src was regulated in a flow magnitude-dependent manner in MDA-MB-231
cells. The 5 and 10 µL/min flow rates activated Lyn-Src (46.8% and 49.6% increase,
respectively, at 60 min) with similar efficacy. The lowest flow rate of 2 µL/min acti-
vated Lyn-Src (14.1% increase at 60 min) to a lesser degree. Lyn-Src activation was
less sensitive to interstitial fluid flow in MCF-10A cells. High fluid flow (10 µL/min)
increased Lyn-Src activity by 12.8% at 60 minutes. Interestingly, an intermediate flow
rate of 5 µL/min decreased Lyn-Src activity by 7.9%. The lowest flow rate did not
alter Lyn-Src activity in MCF-10A mammary cells. This differential effect of varying
flow rates on Lyn-Src has also been shown in chondrocytes under 3D interstitial fluid
flow [48].
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Fig. 3.1.: FAK and Src activities at the lipid raft of the plasma membrane. FRET
ratio images were scaled according to the color bar, which represents the emission
ratio CFP/YFP. (a) Lyn-FAK activity in MDA-MB-231 cells under fluid flow; n=10
(2 µL/min); n=8 (5 µL/min); n=8 (10 µL/min) cells. (b) Lyn-FAK activity in
MCF-10A cells under interstitial fluid flow; n=10 (2 µL/min); n=11 (5 µL/min);
n=11 (10 µL/min) cells. (c) Lyn-Src activity in MDA-MB-231 cells under IFF; n=9
(2 µL/min); n=9 (5 µL/min); n=8 (10 µL/min) cells. (d) Lyn-Src activity in
MCF-10A cells under fluid flow; n=10 (2 µL/min); n=11 (5 µL/min); n=11 (10
µL/min) cells. Scale bar, 10 µm. * p < 0.05.
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3.2 Interstitial fluid flow induces differential, subcellular AMPK activity
in MDA-MB-231 cancer cells
AMPK is the cellular, metabolic stress regulator and a potential downstream
target of Src and FAK, so subcellular AMPK activity was monitored in response to
interstitial fluid flow. Metastatic breast cancer cells (MDA-MB-231) and non-tumor
mammary cells (MCF-10A) were transfected with FRET-based biosensors specific to
various subcellular domains of AMPK cytosol (Cyto-AMPK), mitochondria (Mito-
AMPK), plasma membrane (PM-AMPK), and nucleus (Nuc-AMPK). Cells were then
suspended in 3D in collagen-Matrigel, and the cell-gel mixture was inserted into flow
chambers to polymerize. During imaging, samples were subjected to 2, 5, or 10
µL/min interstitial fluid flows [Fig. 3.2]. Subcellular AMPK activity was monitored
via changes in the YFP/CFP emission ratio for each cell. Only MDA-MB-231 cells
transfected with Mito-AMPK responded significantly to loading. The highest flow
rate (10 µL/min) induced a 9.2% increase in Mito-AMPK activity after 60 minutes
of interstitial fluid flow. Similarly, an intermediate flow rate of 5 µL/min prompted
an 8.1% increase in activation. The lowest flow rate (2 µL/min) only increased the
activity of Mito-AMPK by 3.7% at 60 minutes. This mild activation (less than 5%
increase), while statistically significant, was not considered physiologically relevant.
AMPK activity fluctuates in vivo; therefore, small changes in activity cannot be
attributed to the effects of interstitial fluid flow. Unlike AMPK at mitochondria,
Cyto-AMPK, PM-AMPK, and Nuc-AMPK were not activated by the applied levels
of fluid shear stress in MDA-MB-231. Internal laboratory data also demonstrates
differential, subcellular AMPK activation in 2D.
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Fig. 3.2.: AMPK activities at subcellular domains of MDA-MB-231. FRET ratio
images were scaled according to the color bar, which represents the emission ratio
YFP/CFP. Interstitial fluid flow was applied at time = 0 min. (a) Cyto-AMPK
activity under fluid flow; n=13 (2 µL/min); n=16 (5 µL/min); n=11 (10 µL/min)
cells. (b) Mito-AMPK activity under interstitial fluid flow; n=12 (2 µL/min); n=14
(5 µL/min); n=13 (10 µL/min) cells. (c) PM-AMPK activity under fluid flow; n=11
(2 µL/min); n=11 (5 µL/min); n=12 (10 µL/min) cells. (d) Nuc-AMPK activity
under fluid flow; n=14 (2 µL/min); n=12 (5 µL/min); n=16 (10 µL/min). Scale
bar, 10 µm. * p < 0.05.
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Unlike the breast cancer cell line (MDA-MB-231), subcellular AMPK in non-
tumor mammary cells (MCF-10A) did not respond to interstitial fluid flow. AMPK
activity was monitored in the cytoplasm, mitochondria, plasma membrane, and nu-
cleus, but none of these organelles displayed domain-specific activation [Fig. 3.3].
It is worth noting that, similar to the 3D case, MDA-MB-231 metastatic cancer
cells subjected to 2D fluid flow (a shear stress of 10 dyne/cm2) displayed a 24.0%
increase in Mito-AMPK activity. MCF-10A cells, however, did not alter their Mito-
AMPK activity in response to the same high shear stress. Lower shear (2.5 dyne/cm2)
did not activate Mito-AMPK in either cell type in 2D. Therefore, fluid flow-induced
activation of Mito-AMPK in MDA-MB-231 cells has been observed in both 2D and
3D. This information is important for the cohesiveness of migration experiments,
where random migration assays were performed in 2D.
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Fig. 3.3.: AMPK activities at subcellular domains of MCF-10A. FRET ratio images
were scaled according to the color bar, which represents the emission ratio
YFP/CFP. Interstitial fluid flow was applied at time = 0 min. (a) Cyto-AMPK
activity under fluid flow; n=12 (2 µL/min); n=10 (5 µL/min); n=10 (10 µL/min).
(b) Mito-AMPK activity under interstitial fluid flow; n=13 (2 µL/min); n=13 (5
µL/min); n=13 (10 µL/min). (c) PM-AMPK activity under fluid flow; n=14 (2
µL/min); n=14 (5 µL/min); n=14 (10 µL/min). (d) Nuc-AMPK activity under
fluid flow; n=16 (2 µL/min); n=14 (5 µL/min); n=14 (10 µL/min). Scale bar, 10
µm. * p < 0.05.
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3.3 Src or FAK inhibition abolishes Mito-AMPK activity and response
to interstitial fluid flow in MDA-MB-231
To determine whether the activation of Mito-AMPK in MDA-MB-231 is down-
stream of FAK and Src, both FAK and Src were individually inhibited in 3D culture.
MDA-MB-231 cells transfected with Mito-AMPK were embedded in collagen-Matrigel
and placed in glass-bottom dishes. After a 2-hour incubation period, cells were treated
with a Src inhibitor (PP2, 10 µM) or FAK inhibitor (PF573228, 1 µM). FRET images
were acquired 1, 2, and 4 hours after drug treatment to monitor Mito-AMPK activity
in comparison with an untreated control sample [Fig. 3.4]. Results showed a steady
decline in the basal activity of Mito-AMPK over time. Both Src and FAK global inhi-
bition resulted in consistently lower Mito-AMPK activity compared to the untreated
cells. After 4 hours, cells treated with the FAK inhibitor (PF573228) showed a 9.2%
decrease in Mito-AMPK activity, and cells treated with Src inhibitor (PP2) displayed
a 10.3% decrease in Mito-AMPK activity.
Since Src and FAK inhibition significantly decreased Mito-AMPK activity in
MDA-MB-231, we sought to determine whether similar inhibition could eliminate
the shear stress-induced response of Mito-AMPK to interstitial fluid flow. MDA-MB-
231 cells embedded in collagen gel were injected into flow chambers and incubated for
2 hours for gelation. Chambers were then treated with FAK inhibitor (PF573228, 1
µM) or Src inhibitor (PP2, 10 µM) and subjected to 10 µL/min fluid flow for 1 hour
[Fig. 3.5]. While fluid flow alone increased Mito-AMPK activity by 9.2%, inhibition
of either Src or FAK abolished this response. This showed that FAK and Src acti-
vation are required for the flow-mediated mechanotransduction of Mito-AMPK. The
same is true for MDA-MB-231 cells cultured in 2D, according to internal laboratory
data.
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Fig. 3.4.: Mito-AMPK activity in MDA-MB-231 cells treated with kinase inhibitors
for Src and FAK. After transfection, cells were treated with either 1 µM PP2 (Src
inhibitor) or 10 µM PF573228 (FAK inhibitor). Mito-AMPK activity observed after
1, 2, and 4 hours of treatment. FRET ratio images scaled according to the color bar,
which represents emission ratio YFP/CFP. Scale bar, 10µm. n>13 cells. * p<0.05.
Fig. 3.5.: MDA-MB-231 cells transfected with Mito-AMPK were pretreated with
either 1 µM PP2 (Src inhibitor) or 10 µM PF573228 (FAK inhibitor) for 1 hour
before subjection to interstitial fluid flow (10 µL/min). Activation of Mito-AMPK
by fluid flow was abolished by kinase inhibition. FRET ratio images scaled
according to the color bar, which represents emission ratio YFP/CFP. Scale bar,
10µm. n>14 cells. * p<0.05.
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3.4 Global AMPK activation reduces MDA-MB-231 cell migration
As mentioned previously, augmented global AMPK activity is known to attenuate
cancer cell migration. To determine whether global AMPK activation reduces migra-
tion in MDA-MB-231 breast cancer cells, a random 2D migration assay was used.
MDA-MB-231 cells were tagged with fluorescent GFP dye and seeded inside flow
chambers at low confluency (10%). To study the general role of AMPK in cancer cell
migration, some samples were treated with a global AMPK inhibitor (Compound C, 5
µM) or global AMPK activator (A769662, 25 µM). Individual cells, away from cham-
ber walls and free to migrate, were tracked for 8 hours [Fig. 3.6.]. Results showed
a significant decrease in cancer cell migration in response to global AMPK activa-
tion. The average cell displacement for untreated cells was 158.0 ± 6.8 µm, while the
average displacement for cells treated with global AMPK activator (A769662) was
only 104.0 ± 3.4 µm (a 34.2% decrease). Cells treated with AMPK global inhibitor
(Compound C) displayed a slight increase in average cell migration (168.8 ± 5.4 µm),
though it was not significant; however, this experiment does show that global AMPK
activation affects cancer cell migration. These results are consistent with published
reports on the linkage of global AMPK activation and the decreased migration or
invasion of many cancers, including breast cancer [27,28,31].
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Fig. 3.6.: Random cell migration of MDA-MB-231 treated with global AMPK
activator (A769962, 25 µM) or inhibitor (Compound C, 5 µM) 1 hour before
imaging. (a) Bar graph showing the average displacement of cells over 8 hours;
n=30 (control), n=54 (A769962), n=64 (Compound C) cells. * p<0.05. (b)
Migration tracks (µm) for MDA-MB-231; n=25 cells. (c) Migration tracks (µm) for
MDA-MB-231 treated with global AMPK activator; n=25 cells. (d). Migration
tracks (µm) for MDA-MB-231 treated with global AMPK inhibitor; n=25 cells. The
starting point for each cell migration track was normalized to the origin.
3.5 Mito-AMPK inhibition partially reduces cancer cell migration
While global AMPK activation has been shown to decrease cancer cell migra-
tion [27, 28, 31], some postulate that local AMPK activation at various subcellular
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domains may play different or even antagonistic roles [29, 30, 33, 49]. As mentioned
previously, cancer cells display decreased global AMPK activity [29, 30]. This leaves
the metabolism of cancer cells unchecked, allowing them to grow, proliferate, and
migrate more freely [15, 27, 28, 31]. It is also widely accepted that increased intersti-
tial fluid flow at the tumor site induces metastasis [3–5, 7, 9]. However, as we have
shown in this study, interstitial fluid flow increases subcellular Mito-AMPK activ-
ity in MDA-MB-231 cells. If fluid shear stress increases Mito-AMPK and migration
simultaneously, then Mito-AMPK may have an augmenting, rather than inhibitory,
effect on migration. To test this hypothesis, the role of Mito-AMPK in cancer cell
migration was explored. MDA-MB-231 cells were transfected with a Mito-AMPK-
specific inhibitory peptide (Tom20 AIP) and seeded in collagen-coated flow chambers.
Individual cells were tracked for 8 hours in a random migration assay. Cells trans-
fected with Tom20 AIP showed partially reduced migration [Fig. 3.7c]. The average
cell displacement for Tom20 AIP transfected cells was 136.0 5.3 µm (13.9% decrease
compared to control). To ensure that decreased migration was not simply a result of
transfection, cells transfected with Mito-AMPK were also considered. Transfecting
MDA-MB-231 with a FRET biosensor did not significantly affect migration [data not
shown].
3.6 Mito-AMPK inhibition eliminates migration response to interstitial
fluid flow
Next, we examined the effect of fluid flow on cancer cell migration, which is
known to specifically increase Mito-AMPK activity. MDA-MB-231 cells were plated
in collagen-coated flow chambers and subjected to 2D fluid flow. A peristaltic pump
was used to apply shear flow at a volumetric flow rate of 10.6 mL/min, which cor-
responds to a 10 dyne/cm2 shear stress. Cells subjected to 8 hours of unidirectional
fluid flow showed a slight increase in cancer cell migration [Fig. 3.7d]. The average cell
displacement was 171.7 ± 4.7 µm, which is an 8.0% increase compared to the control.
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This affirmed the notion that fluid shear stress increases cancer cell metastatic poten-
tial. To determine whether Mito-AMPK activation in response to flow played a part
in enhancing migration, cancer cells were both transfected with Tom20 AIP (Mito-
AMPK inhibitor) and subjected to 10 dyne/cm2 fluid flow [Fig. 3.7e]. Inhibition of
Mito-AMPK completely abolished the migration response to fluid flow. The average
cell displacement was reduced to 132.1 ± 6.9 µm (a 16.4% decrease). This suggests
that Mito-AMPK activation was necessary for the flow-induced migration response
of breast cancer cells. Since global AMPK activation is linked to suppressed cancer
cell migration, yet flow-induced Mito-AMPK activation correlates with increased mi-
gration, one must assume that AMPK plays different roles in migration depending
on its subcellular location.
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Fig. 3.7.: Random cell migration of MDA-MB-231 transfected with Mito-AMPK
inhibitor peptide (Tom20 AIP), subjected to fluid flow (10 dyne/cm2), or both. (a)
Bar graph showing the average displacement of cells over 8 hours; n=30 (control),
n=36 (Tom20 AIP), n=41 (fluid flow), n=39 (Tom20 AIP + fluid flow) cells. *
p<0.05. (b) Migration tracks (µm) for MDA-MB-231; n=25 cells. (c) Migration
tracks (µm) for MDA-MB-231 transfected with Mito-AMPK inhibitor (Tom20
AIP); n=25 cells. (d). Migration tracks (µm) for MDA-MB-231 subjected to fluid
flow (10 dyne/cm2); n=25 cells. (e) Migration tracks (µm) for MDA-MB-231
transfected with Mito-AMPK inhibitor (Tom20 AIP) and subjected to fluid flow (10
dyne/cm2); n=25 cells. The starting point for each cell migration track was
normalized to the origin.
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4. DISCUSSION
In this study we employed a 3D type I collagen-Matrigel model in conjunction
with live cell imaging to determine the real-time activation of FAK, Src, and sub-
cellular AMPK in response to interstitial fluid flow. Overall, MDA-MB-231 cancer
cells were more mechanosensitive than MCF-10A non-tumor epithelial breast cells.
Our results verified that mechanotransduction of membrane-bound FAK and Src is
flow magnitude-dependent. For example, a low flow rate (2 µL/min) did not greatly
activate Lyn-FAK or Lyn-Src in either MDA-MB-231 or MCF-10A cells. The high-
est flow rate (10 µL/min), however, increased Lyn-Src activity in both cell types
and significantly increased Lyn-FAK activity in cancer cells. This data indicates a
shear stress threshold for integrin-associated kinase activation in MCF-10A cells. A
higher activation threshold in normal MCF-10A suggests that MDA-MB-231 cancer
cells, which up-regulate Src and FAK expression, are more sensitive to mechanical
stimulation [24–26].
We identified the metabolic regulator AMPK as a potential downstream target
of FAK/Src signaling in response to fluid shear stress. In our study, interstitial
fluid flow induced differential, subcellular AMPK activity in cancer cells. Since flow
rates ranging from 2-10 µL/min are known to induce differential Src/FAK activation,
subcellular AMPK activation along this integrin-mediated signaling axis must occur
within the same range. Subcellular AMPK within MCF-10A normal epithelial cells
did not respond to mechanical loading via IFF. In contrast, MDA-MB-231 metastatic
cancer cells showed increased Mito-AMPK activation in a flow-magnitude dependent
manner. Higher flow induced higher AMPK activity in the mitochondrial domain.
To determine whether Mito-AMPK activity is Src/FAK-dependent, cancer cells were
treated with Src or FAK inhibitors. Separate inhibition of Src or FAK reduced Mito-
AMPK basal activity and abolished the response of Mito-AMPK to interstitial fluid
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flow (10 µL/min). Whether the linkage between integrin/Src/FAK and Mito-AMPK
is mechanical is unknown. Mitochondrial AMPK is located on the outer membrane
of the organelles [28,32,50]. Activation of Mito-AMPK is required for mitochondrial
turnover (mitophagy), fusion, and fission, enabling the dynamic plasticity of the mi-
tochondria network in response to stress [28,50]. Mitochondria localize preferentially
along microtubules of the cytoskeleton, and they use microtubules as tracks to guide
their movement within cells [33, 50–52]. It is possible that integrin-mediated signal-
ing is transmitted via FAK/Src through the actin cytoskeleton, which connects to the
microtubular network as well.
AMPK activation at mitochondria also plays a role in cell migration. Mito-
chondria regulate calcium homeostasis needed for polarity and cell migration [52].
MDA-MB-231 cancer cells cannot migrate effectively when mitochondrial genes for
calcium regulatory proteins are perturbed [52]. During cell migration, mitochondria
reposition strategically along microtubules, which polymerize toward cellular exten-
sions [33,51,52]. Interestingly, AMPK controls the speed of microtubule polymeriza-
tion toward focal adhesions [51]. Previous work showed localized, subcellular AMPK
activation at mitochondria as they were trafficked toward the leading edge of cells
during migration [33]. The results of our study also highlight the importance of Mito-
AMPK activation in MDA-MB-231 cancer cell migration. Inhibition of Mito-AMPK
partially reduces cell motility and abolishes the fluid flow-induced enhancement of
migration. In contrast, global AMPK activation significantly reduced migration of
MDA-MB-231. If global AMPK is down-regulated in cancer cells [27, 28, 31] and
global AMPK activation reduces metastatic potential, how can subcellular AMPK
activation at mitochondria promote migration? Our results affirm the notion that
localized AMPK activities at various subcellular domains have dual (or even antag-
onistic) functions [28, 32, 33], particularly in MDA-MB-231 breast cancer migration.
Our results suggest that the weighted net effect of these functions determines overall
cell behavior.
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5. CONCLUSIONS AND FUTURE DIRECTIONS
Breast tumors alter their biophysical environment by increasing ECM stiffness
and interstitial fluid flow. High levels of IFF affect cancerous tissue differently than
healthy mammary tissue, and shear stress stimulates integrin-mediated signaling
within cancer cells. Ultimately, the mechanotransduction initiated at focal adhesions
by IFF enhances cancer cell migration away from the primary tumor site as they
invade the surrounding stroma. In this study, we have shown that integrin-associated
kinases Src and FAK can be regulated by IFF. Similarly, subcellular AMPK can be
differentially activated in MDA-MB-231 breast cancer cells by IFF along the Src-
FAK signaling axis. We showed that global AMPK activation attenuates MDA-MB-
231 breast cancer cell migration while fluid shear stress induces migration. Finally,
it was revealed that subcellular AMPK activation at mitochondria is necessary for
fluid flow-induced migration of MDA-MB-231 breast cancer cells. The dual, and
somewhat contradictory, nature of AMPK at different domains suggests that fluid
flow-induced migration of MDA-MB-231 is determined by the weighted net effect
of subcellular AMPK activities. For conclusive results concerning breast cancer cell
behavior, a more expansive variety of cell types should be used. Additionally, the
domain-dependent signaling of AMPK is active in every metabolic process, not only
migration. For future work, AMPK in other subcellular domains in cancer cell migra-
tion should be continued, and other behaviors, such as cell proliferation [15], should
be explored.
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